Hung-Kai Chen , M.S.

Henry Chen

Contact Information


  • Ph.D. student in Pharmaceutical Outcomes & Policy, 08/2022-Present
  • M.S. in Clinical Pharmacy, National Cheng Kung University (NCKU), 09/2018-06/2020
  • B.S. in Pharmacy, Taipei Medical University (TMU), 09/2014-06/2018

Entry Date into the POP Graduate program

  • Fall 2022

Research Interests

  • I am interested in applying pharmacoepidemiologic methods to investigate the real-world effectiveness and safety outcomes of medications, especially for patients with rheumatic disease and cancer.

Professional Experience

  • Research Assistant, Linkou Chang Gung Memorial Hospital, 12/2020-06/2022
  • Clinical Pharmacist, NCKU Hospital, 10/2018-07/2020

Scholarships and Awards

  • NCKU SinoPac Scholarship, 2019-2020
  • TMU Presidential Award, 2017
  • Yin Shu-Tien Educational Foundation Scholarship, 2016-2017


  • Risk of Heart Failure in Rheumatoid Arthritis Patients Treated with Tumour Necrosis Factor-α Inhibitors. Clinical Pharmacology & Therapeutics.
  • Long Term Use and Risk of Major Adverse Cardiac Events Between Abiraterone and Enzalutmide in Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer. Abstract accepted by ISPE’s 14th Asian Conference on Pharmacoepidemiology (ACPE14).
  • Effectiveness of Minimally Invasive Hepatectomy in Patients with Early or Intermediate-stage Hepatocellular Carcinoma: A Multi-institutional Cohort Study. Abstract accepted by ISPE’s ACPE14